Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Nicox SA
Deal Size : $32.8 million
Deal Type : Licensing Agreement
Nicox to Gain 3 Million in 2025 Milestones as NCX 470 Heads to Phase 3 in Japan
Details : Under the licensing agreement, Kowa holds the Japanese rights to research & development and commercialize NCX 470 (bimatoprost). It is being evaluated for the treatment of ocular hypertension.
Product Name : NCX 470
Product Type : HPAPI
Upfront Cash : $3.2 million
May 27, 2025
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Nicox SA
Deal Size : $32.8 million
Deal Type : Licensing Agreement
Lead Product(s) : K-679
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
K-679 Unimicelle Drug Shows Efficacy in EGFR-Positive Solid Tumors
Details : K-679 is a novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs.
Product Name : K-679
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 21, 2025
Lead Product(s) : K-679
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
